News
-
Exciting job opportunities available in The Midlands
over 7 years ago by John Reid
Exciting job opportunities in The Midlands: At the RFT Group we have the privilege of been a Preferred Supplier of quality candidates to many exceptional forward thinking and innovative companies and as a result we are extremely busy, I have many exciting opportunities with a number of major multinational healthcare companies in The Midlands ...
Read More -
Brexit impact on pharma
over 7 years ago by Gerry Kennedy
Although much uncertainty abounds as to the ‘how’ and ‘when’ of the unprecedented procedure of a member state leaving the EU, a few downsides and pitfalls can already be identified in terms of the implications for the European pharmaceutical sector and the impact on how pharmaceutical companies do business in and with the UK. An immediate imp...
Read More -
Big pharma wants food producers to switch from antibiotics to vaccines
over 7 years ago by Gerry Kennedy
Eli Lilly ($LLY) recently opened a 48,000-square-foot research facility near Indianapolis that’s operated by its animal health division, Elanco, and that has one overriding goal: to develop vaccines that food producers can use in place of the antibiotics that they’re under increasing pressure to eliminate. In January, mandatory rules instituted ...
Read More -
The dream is dead
over 7 years ago by Gerry Kennedy
Roche ($ROG) and Inovio Pharmaceuticals ($INO) had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that dream is officially dead as Roche has returned the second of two candidates and discontinued its partnership with Inovio. Inovio slipped about 8% in early trading on the n...
Read More -
Adicet Bio secures a 5 year deal with Regeneron
over 7 years ago by Gerry Kennedy
A scant 6 months after rounding up $51 million in a Series A round led by OrbiMed that also included Novartis Venture Fund, Adicet Bio has secured a 5-year deal with Regeneron Pharmaceuticals ($REGN). The biopharma will pay $25 million up front and research funding to develop multiple clinical candidates for various hematological and solid tumor...
Read More